Paper
0
Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial
Authors
Thomas Walsh,Issam Raad
Thomas Patterson,Pranatharthi Chandrasekar,Gerald Donowitz,Richard Graybill,Reginald Greene,Ray Hachem,Susan Hadley,Raoul Herbrecht,Amelia Langston,Arnold Louie,Patricia Muñóz,Brahm Segal,David Stevens,Jo‐Anne Young,Charles White,Gavin Corcoran,Jagadish Gogate,Gopal Krishna,Lisa Pedicone,C. Hardalo
+20 authors
,John PerfectJournal
Published
Dec 1, 2006
Show more
Save
Tip0
TipSave
Abstract
Background. Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Current treatments provide limited benefit. Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity against Aspergillus species.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.